


**Company****GEXVal Inc.****Presenter****Juran  
Kato**

- **Origin:** a spinoff company from Takeda, since April 1<sup>st</sup>, 2018
- **Focus:** 1) orphan/Intractable disease  
2) early development projects up to Ph2 (quick PoC)
- **Strength:** creative repositioning of early terminates, never marketed
- **Pipeline:** two development projects and three discovery projects

**GEXVal**

**We are actively seeking partners for R&D  
and Series B funding.**


**Our presentation at Pitch Session: Oct 11<sup>th</sup>**

## Pipeline

- Neuroscience rare disease
- Pulmonary arterial hypertension
- Cardiomyopathies
- Periodontitis
- Irritable Bowel Syndrome-diarrhea (IBS-D)

## Creative repositioning for high value and productivity

- Drug repositioning
- Orphan and intractable diseases
- GPCR modulators
- External partnerships



$$\square + + = 叶$$



'wish Comes True'

## Contact us

GEXVal Inc. @ Shonan iPark

2-26-1, Muraoka-Higashi, Fujisawa, Kanagawa 251-0012, Japan

[mami.ojima@gexval.com](mailto:mami.ojima@gexval.com) (Japanese), [lili.mao@gexval.com](mailto:lili.mao@gexval.com) (English, Chinese)